Equities research analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to post earnings of ($0.16) per share for the current quarter, Zacks reports. Four analysts have made estimates for Abeona Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.20). Abeona Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 23.8%. The business is expected to announce its next earnings results on Tuesday, August 21st.
According to Zacks, analysts expect that Abeona Therapeutics will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.34). For the next financial year, analysts forecast that the firm will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.98) to ($0.29). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. Abeona Therapeutics had a negative return on equity of 23.57% and a negative net margin of 939.83%. The business had revenue of $2.60 million during the quarter, compared to the consensus estimate of $0.27 million.
Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its stake in Abeona Therapeutics by 89.8% in the fourth quarter. Bank of New York Mellon Corp now owns 195,474 shares of the biopharmaceutical company’s stock valued at $3,097,000 after buying an additional 92,465 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $346,000. EAM Investors LLC lifted its stake in Abeona Therapeutics by 50.3% in the fourth quarter. EAM Investors LLC now owns 221,175 shares of the biopharmaceutical company’s stock valued at $3,506,000 after buying an additional 74,002 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $163,000. Finally, Virtu Financial LLC purchased a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $246,000. Institutional investors own 69.11% of the company’s stock.
Shares of Abeona Therapeutics stock traded down $0.20 on Friday, reaching $15.90. 850,422 shares of the company were exchanged, compared to its average volume of 1,082,414. Abeona Therapeutics has a 1-year low of $4.55 and a 1-year high of $22.75. The company has a market cap of $749.79 million, a PE ratio of -23.94 and a beta of 1.27.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.